A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Exclusion Criteria

• •Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
• •Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
• •Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.